The IMpower133 clinical trial is an international, double‐blind, randomized, placebo‐controlled phase III trial, which evaluated the efficacy and safety of FL treatment with etoposide plus carboplatin in combination with atezolizumab (anti‐PD‐L1 inhibitor) compared to chemotherapy combined with placebo in treatment‐naive ES‐SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.